Nathan Segall

1.2k total citations
27 papers, 583 citations indexed

About

Nathan Segall is a scholar working on Immunology and Allergy, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nathan Segall has authored 27 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Immunology and Allergy, 12 papers in Physiology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nathan Segall's work include Allergic Rhinitis and Sensitization (13 papers), Asthma and respiratory diseases (12 papers) and Respiratory and Cough-Related Research (8 papers). Nathan Segall is often cited by papers focused on Allergic Rhinitis and Sensitization (13 papers), Asthma and respiratory diseases (12 papers) and Respiratory and Cough-Related Research (8 papers). Nathan Segall collaborates with scholars based in United States, Belgium and Switzerland. Nathan Segall's co-authors include Robert A. Wood, S. Ahlstedt, P. Brock Williams, Alan L. Schocket, Anne Schuind, Robert A. Nathan, David Gonzales, L. Herrero, Mitchell Nides and Alan Metz and has published in prestigious journals such as Journal of Allergy and Clinical Immunology, The Journal of Infectious Diseases and Journal of Hepatology.

In The Last Decade

Nathan Segall

27 papers receiving 551 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nathan Segall United States	13	260	190	155	135	76	27	583
Chandramani Panjabi India	13	231 0.9×	133 0.7×	74 0.5×	29 0.2×	210 2.8×	26	506
Michael R. Nelson United States	14	81 0.3×	153 0.8×	42 0.3×	39 0.3×	20 0.3×	31	614
Suzi McCarthy Australia	9	145 0.6×	95 0.5×	48 0.3×	157 1.2×	55 0.7×	13	520
Robin Gore United Kingdom	15	528 2.0×	247 1.3×	231 1.5×	24 0.2×	460 6.1×	32	1.0k
Elżbieta Maciorkowska Poland	11	111 0.4×	66 0.3×	57 0.4×	59 0.4×	31 0.4×	58	556
Sara Tomičić Sweden	6	124 0.5×	120 0.6×	61 0.4×	24 0.2×	27 0.4×	8	458
Victoria Martin United States	10	34 0.1×	134 0.7×	128 0.8×	40 0.3×	20 0.3×	22	434
S. K. Kabra India	13	80 0.3×	29 0.2×	143 0.9×	83 0.6×	152 2.0×	37	484
Annamari Patja Finland	5	108 0.4×	108 0.6×	139 0.9×	14 0.1×	29 0.4×	5	369
Nick Makwana United Kingdom	9	54 0.2×	261 1.4×	90 0.6×	30 0.2×	15 0.2×	18	430

Countries citing papers authored by Nathan Segall

Since Specialization

Citations

This map shows the geographic impact of Nathan Segall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan Segall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan Segall more than expected).

Fields of papers citing papers by Nathan Segall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan Segall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan Segall. The network helps show where Nathan Segall may publish in the future.

Co-authorship network of co-authors of Nathan Segall

This figure shows the co-authorship network connecting the top 25 collaborators of Nathan Segall. A scholar is included among the top collaborators of Nathan Segall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nathan Segall. Nathan Segall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Segall, Nathan, S. Block, Judith Absalon, et al.. (2025). Safety and immunogenicity of a booster dose of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 2, open-label extension of a phase 1/2 randomised controlled trial. The Lancet Infectious Diseases. 25(10). 1138–1148. 2 indexed citations

Absalon, Judith, Nathan Segall, Stan L. Block, et al.. (2020). Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial. The Lancet Infectious Diseases. 21(2). 263–274. 89 indexed citations

Vesikari, Timo, Joanne M. Langley, Nathan Segall, et al.. (2020). Higher proportion of responders with hepatitis B antibody levels ≥ 100 miu/ml with the trivalent HepB vaccine, Sci-B-Vac, compared to Engerix-B: results from the phase 3 double-blind, randomized study comparing immunogenicity and safety (PROTECT). Journal of Hepatology. 73. S579–S579. 2 indexed citations

Turner, M., Peter Winkle, Nathan Segall, et al.. (2020). Immunogenicity and safety of lyophilized and liquid dengue tetravalent vaccine candidate formulations in healthy adults: a randomized, phase 2 clinical trial. Human Vaccines & Immunotherapeutics. 16(10). 2456–2464. 24 indexed citations

Standaert, Baudouin, Stephan Bart, Laurence Chu, et al.. (2019). Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study. Health and Quality of Life Outcomes. 17(1). 80–80. 8 indexed citations

Strezova, Ana, Himal Lal, Laura Cámpora, et al.. (2019). The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial. Vaccine. 37(39). 5877–5885. 21 indexed citations

Ferguson, Murdo, Eric Sheldon, Nathan Segall, et al.. (2017). Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial. Vaccine. 35(10). 1431–1439. 10 indexed citations

Segall, Nathan, Murdo Ferguson, Louise Frenette, et al.. (2016). Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults. The Journal of Infectious Diseases. 214(11). 1717–1727. 37 indexed citations

Hampel, Frank C., et al.. (2015). No hypothalamic-pituitary-adrenal function effect with beclomethasone dipropionate nasal aerosol, based on 24-hour serum cortisol in pediatric allergic rhinitis. Annals of Allergy Asthma & Immunology. 115(2). 137–142. 6 indexed citations

10.

Schuind, Anne, Nathan Segall, Mamadou Dramé, & Bruce L. Innis. (2015). Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial. The Journal of Infectious Diseases. 212(4). 531–541. 17 indexed citations

11.

Georges, George, et al.. (2014). Effect of intranasal triamcinolone acetonide on basal hypothalamic‐pituitary‐adrenal axis function in children with allergic rhinitis. Allergy and Asthma Proceedings. 35(2). 163–170. 5 indexed citations

12.

Storms, William W., Nathan Segall, Lyndon E. Mansfield, et al.. (2013). Efficacy and safety of beclomethasone dipropionate nasal aerosol in pediatric patients with seasonal allergic rhinitis. Annals of Allergy Asthma & Immunology. 111(5). 408–414.e1. 18 indexed citations

13.

Segall, Nathan, et al.. (2012). Once Daily Treatment with Beclomethasone Dipropionate Hydrofluoroalkane Nasal Aerosol Is Safe and Effective in Children (6-11 Years of Age) With Seasonal Allergic Rhinitis. Journal of Allergy and Clinical Immunology. 129(2). AB188–AB188. 2 indexed citations

14.

Segall, Nathan, et al.. (2010). Efficacy and safety of levocetirizine in improving symptoms and health-related quality of life in US adults with seasonal allergic rhinitis: a randomized, placebo-controlled study. Annals of Allergy Asthma & Immunology. 104(3). 259–267. 21 indexed citations

15.

Kaliner, Michael, et al.. (2009). Research abstracts presented at the Western Society of Allergy, Asthma, and Immunology Meeting, January 25‐29, 2009. Allergy and Asthma Proceedings. 30(2). 210–210. 1 indexed citations

16.

Hampel, Frank C., Ashish Kumar Nayak, Nathan Segall, et al.. (2009). Research abstracts presented at the Southwest Allergy Forum, January 14‐18, 2009. Allergy and Asthma Proceedings. 30(2). 209–209. 1 indexed citations

17.

Wood, Robert A., Nathan Segall, S. Ahlstedt, & P. Brock Williams. (2007). Accuracy of IgE antibody laboratory results. Annals of Allergy Asthma & Immunology. 99(1). 34–41. 83 indexed citations

18.

Gonzales, David, Mitchell Nides, Linda Hyder Ferry, et al.. (2001). Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo‐controlled study. Clinical Pharmacology & Therapeutics. 69(6). 438–444. 112 indexed citations

19.

Azaz, B., et al.. (1995). Case of thromboangiitis obliterans (Buerger's disease) of the upper lip. American Journal of Otolaryngology. 16(4). 269–271. 2 indexed citations

20.

Nathan, R.A., et al.. (1979). The effects of H1 and H2 antihistamines on histamine inhalation challenges in asthmatic patients.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 120(6). 1251–8. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact